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Abstract
Previously, we found that high doses of genistein show 
an inhibitory effect on uterine leiomyoma (UtLM) cell 
proliferation. In this study, using microarray analysis 
and  Ingenuity  Pathways  Analysis
TM,  we  identified 
genes (up- or down-regulated, ≥ 1.5 fold, P ≤ 0.001), 
functions and signaling pathways that were altered fol-
lowing treatment with an inhibitory concentration of 
genistein (50 μg/ml) in UtLM cells. Downregulation of 
TGF-β signaling pathway genes, activin A, activin B, 
Smad3, TGF-β2 and genes related to cell cycle regu-
lation, with the exception of the upregulation of the 
CDK inhibitor P15, were identified and validated by re-
al-time RT-PCR studies. Western blot analysis further 
demonstrated decreased protein expression of activin 
A  and  Smad3  in  genistein-treated  UtLM  cells. 
Moreover,  we  found  that  activin  A  stimulated  the 
growth of UtLM cells, and the inhibitory effect of genis-
tein was partially abrogated in the presence of activin 
A. Overexpression of activin A and Smad3 were found 
in tissue samples of leiomyoma compared to matched 
myometrium, supporting the contribution of activin A 
and Smad3 in promoting the growth of UtLM cells. 
Taken  together,  these  results  suggest  that  down-
regulation of activin A and Smad3, both members of the 
TGF-β pathway, may offer a mechanistic explanation 
for the inhibitory effect of a high-dose of genistein on 
UtLM cells, and might be potential therapeutic targets 
for treatment of clinical cases of uterine leiomyomas.
Keywords: activin A; genistein; leiomyoma; myome-
trium;  oligonucleotide  array  sequence  analysis; 
Smad3 protein; transforming growth factor β 
Introduction
Uterine leiomyomas (i.e., fibroids, myomas) are the 
leading indication for hysterectomy in the United 
States with the estimated cumulative incidence of 
tumors by age 50 being ＞80% for black women 
and nearly 70% for white women in the United 
States (Walker and Stewart, 2005; Viswanathan et 
al., 2007). These tumors represent a tremendous 
public health burden and economic cost to society. 
At present, surgical intervention is still the standard 
and most effective treatment for uterine leiomyomas 
(Rackow and Arici, 2006; Tulandi, 2007). Although 
therapeutic agents, such as gonadotropin-releasing 
hormone (GnRH) agonists are being used clinically 
(Chegini et al., 2002), and selective estrogen-receptor 
modulators (SERMs) (Liu et al., 2007), selective pro-
gesterone-receptor modulators (SPRMs) (Chwalisz et 282    Exp. Mol. Med. Vol. 44(4), 281-292, 2012
Gene function  Genes  Accession No.  Description Fold change 
Cancer 
C5ORF13  NM_004772  Chromosome 5 open reading frame 13  -4.45 
CASP3 NM_004346  Caspase  3,  apoptosis-related cysteine protease  -1.65 
CAV1  BC006432  Caveolin 1, caveolae protein, 22kDa  -2.84 
CLG  AK026111  Likely ortholog of mouse common-site lymphoma/leukemia GEF  -1.97 
CNN2 NM_004368  Calponin  2  -1.9 
CST NM_004861  Galactose-3-O-sulfotransferase  1  3.7 
CYR61  Z97068  Cysteine-rich, angiogenic inducer, 61  -2.47 
ENC1  AY049781  Ectodermal-neural cortex (with BTB-like domain)  -2.72 
FGF5  M37825  Fibroblast growth factor 5  -2.14 
FGF13  NM_004114  Fibroblast growth factor 13  -2.06 
FGFR3  NM_000142  Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric 
dwarfism) 
1.85 
HAS2 NM_005328  Hyaluronan  synthase  2  -4.88 
HMGA2  NM_003483  High mobility group AT-hook 2  -3.06 
HMOX1  NM_002133  Heme oxygenase (decycling) 1  4.99 
ID1  NM_002165  Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein  1.67 
ID3  NM_002167  Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein  1.54 
ID4  U16153  Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein  2.68 
IGF2R  NM_000876  Insulin-like growth factor 2 receptor  1.89 
IRS1  NM_005544  Insulin receptor substrate 1  1.6 
IRS2  AF073310  Insulin receptor substrate 2  7.88 
MMP1 NM_002421  Matrix metalloproteinase 1 (interstitial collagenase)  -2.26 
MMP14 NM_004995  Matrix metalloproteinase 14 (membrane-inserted)  1.88 
RARB NM_000965  Retinoic acid receptor, beta  -1.84 
SHC1 NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
TGFB2 AK021874  Transforming growth factor, beta 2  -3.03 
TGFBR3 NM_003243  Transforming growth factor, beta receptor III (betaglycan, 300kDa)  1.52 
VEGF AK098750  Vascular endothelial growth factor  -1.6 
VEGFC NM_005429  Vascular endothelial growth factor C  -2.92 
Cell cycle 
MYBL1 X66087  v-myb myeloblastosis viral oncogene homolog (avian)-like 1  -3.41 
PDGFRA NM_006206  Platelet-derived growth factor receptor, alpha polypeptide  -2.63 
HGF X16323  Hepatocyte growth factor (hepapoietin A; scatter factor)  -2.32 
SHC1 NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
RAD21 NM_006265  RAD21 homolog (S. pombe)  -1.69 
CASP3 NM_004346  Caspase  3,  apoptosis-related cysteine protease  -1.65 
VEGF  AK098750  Vascular endothelial growth factor  -1.6 
IRS1  NM_005544  Insulin receptor substrate 1  1.6 
PLK3  NM_004073  Polo-like kinase 3 (Drosophila)  2.25 
PCNA  NM_002592  Proliferating cell nuclear antigen  2.36 
IL6R  X12830  Interleukin 6 receptor  3.11 
HMOX1  NM_002133  Heme oxygenase (decycling) 1  4.99 
PLAB  NM_004864  Growth differentiation factor 15  7.57 
IRS2  AF073310  Insulin receptor substrate 2  7.88 
Cell death 
EGR1  NM_001964  Early growth response 1  -6.76 
MYBL1  X66087  v-myb myeloblastosis viral oncogene homolog (avian)-like 1  -3.41 
PDGFRB  NM_002609  Platelet-derived growth factor receptor, beta polypeptide  -3.25 
TGFB2  AK021874  Transforming growth factor, beta 2  -3.03 
VEGFC  NM_005429  Vascular endothelial growth factor C  -2.92 
CDK6 BC027989  Cyclin-dependent  kinase  6  -2.91 
SHC3  NM_016848  Src homology 2 domain containing transforming protein C3  -2.35 
MMP1  NM_002421  Matrix metalloproteinase 1 (interstitial collagenase)  -2.26 
Table 1. Functions and genes
a that were significantly altered in uterine leiomyoma (UtLM) cells following genistein (50 μg/ml) treatment for
24 hGenistein regulates TGFβ pathway genes    283
Gene function  Genes  Accession No.  Description Fold change 
FGF5  M37825  Fibroblast growth factor 5  -2.14 
CDK5 NM_004935  Cyclin-dependent  kinase  5  -1.87 
SHC1  NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
PCNA  NM_002592  Proliferating cell nuclear antigen  2.36 
IRS2  AF073310  Insulin receptor substrate 2  7.88 
Cell signaling 
IRS1  NM_005544  Insulin receptor substrate 1  1.6 
OXTR NM_000916  Oxytocin  receptor  -3.32 
TRPV1  NM_080706  Transient receptor potential cation channel, subfamily V, member 1  2.56 
Cell-to-cell signaling and interaction 
ESM1  NM_007036  Endothelial cell-specific molecule 1  -8.99 
CASP3 NM_004346  Caspase  3,  apoptosis-related cysteine protease  -1.65 
VEGF  AK098750  Vascular endothelial growth factor  -1.6 
BSN NM_003458  Bassoon  (presynaptic cytomatrix protein)  5.32 
IRS2  AF073310  Insulin receptor substrate 2  7.88 
Cellular growth and proliferation 
IRS2  AF073310  Insulin receptor substrate 2  7.88 
IL6R  X12830  Interleukin 6 receptor  3.11 
CDKN1C  NM_000076  Cyclin-dependent kinase inhibitor 1C (p57, Kip2)  2.36 
PCNA  NM_002592  Proliferating cell nuclear antigen  2.36 
IGF2R  NM_000876  Insulin-like growth factor 2 receptor  1.89 
FGFR3  NM_000142  Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric 
dwarfism) 
1.85 
IRS1  NM_005544  Insulin receptor substrate 1  1.6 
VEGF  AK098750  Vascular endothelial growth factor  -1.6 
CASP3 NM_004346  Caspase  3,  apoptosis-related cysteine protease  -1.65 
DLG7  NM_014750  Discs, large homolog 7 (Drosophila)  -1.94 
EGR1  NM_001964  Early growth response 1  -6.76 
PHLDA1  BC037430  Pleckstrin homology-like domain, family A, member 1  -13.74 
aIdentified by analysis using Ingenuity Pathway Analysis software.
Table 1. Continued
al., 2005), anti-fibrotic agents and growth factor an-
tagonists (Rackow and Arici, 2006) were assessed 
experimentally for the treatment of these tumors, 
there is still a paucity of effective nonsurgical 
therapies. Therefore, searching for potential novel 
targets for fibroids treatment is a major goal in this 
field. 
        Recently, microarray analysis has provided a 
novel means of elucidating the mechanisms of 
fibroid development (Leppert et al., 2006; Pan et al., 
2007; Litovkin et al., 2008). For example, gene 
microarray was used to characterize the molecular 
environment of leiomyomas and matched myometrium 
during growth, as well as gene expression profiles of 
leiomyoma and myometrial-derived smooth muscle 
cells in response to (TGF-β) and GnRH (Levens et 
al., 2005). Numerous genes have been found to be 
differentially expressed in leiomyoma and myometrial 
tissues (Litovkin et al., 2008). Moreover, based on 
the results of microarray studies, much emphasis 
has been placed on the roles of the extracellular 
matrix (ECM), TGF-β and collagen composition in 
fibroid development (Leppert et al., 2006). 
    Genistein, the major isoflavone in soy, has been 
shown in vivo to be beneficial in the prevention of a 
wide variety of chronic diseases, including cancer 
(Gupta et al., 2010). Furthermore, at high doses (≥
25 μM) that can be reached in cell culture models, 
genistein shows multidirectional actions, such as 
inhibition of tyrosine kinase and DNA topoisomerase 
activities, synthesis and release of TGF-β and 
increased apoptosis in the live cell (Polkowski and 
Mazurek, 2000). In an earlier study, we found that 
high doses of genistein (≥10  μg/ml) had an 
inhibitory effect on uterine leiomyoma (UtLM) cells 
(Moore  et al., 2007). Because increased cell 
proliferation is believed to be the most significant 
contributor to the growth of uterine leiomyomas 
(Dixon et al., 2002; Leppert et al., 2006), we thought 
that microarray analysis of the inhibitory effect of a 
high-dose of genistein (50 μg/ml) on UtLM cells 
might offer insight on genes and pathways that may 
be important in arresting the growth of UtLM cells. 
These data would also provide novel ideas to better 284    Exp. Mol. Med. Vol. 44(4), 281-292, 2012
Signaling pathways  Genes  Accession No.  Description  Fold change 
Apoptosis signaling pathway 
BID NM_001196  BH3 interacting domain death agonist  -1.86 
CASP3 NM_004346  Caspase  3,  apoptosis-related cysteine protease  -1.65 
MAP3K14  NM_003954  Mitogen-activated protein kinase kinase kinase 14  -1.67 
TNFRSF6  NM_000043  Tumor necrosis factor receptor superfamily, member 6  -1.62 
Cell cycle G1S checkpoint regulation pathway 
CDK6 BC027989  Cyclin-dependent  kinase  6  -2.91 
CDKN2B  NM_078487  Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)  2.2 
E2F4  BC033180  E2F transcription factor 4, p107/p130-binding  -1.61 
MADH3  U68019  SMAD, mothers against DPP homolog 3 (Drosophila)  -1.78 
TGFB2  AK021874  Transforming growth factor, beta 2  -3.03 
MYBL1  X66087  v-myb myeloblastosis viral oncogene homolog (avian)-like 1  -3.41 
Cell cycle G2M DNA damage checkpoint regulation pathway 
CCNB2 NM_004701  Cyclin  B2  -1.96 
YWHAE U28936  Tyrosine  3-monooxygenase/tryptophan  5-monooxygenase 
activation protein, epsilon polypeptide 
-1.62 
Death receptor signaling pathway 
BID  NM_001196  BH3 interacting domain death agonist  -1.86 
CASP3 NM_004346  Caspase  3,  apoptosis-related cysteine protease  -1.65 
MAP3K14  NM_003954  Mitogen-activated protein kinase kinase kinase 14  -1.67 
TNFRSF6  NM_000043  Tumor necrosis factor receptor superfamily, member 6  -1.62 
ERK MAPK signaling pathway 
DUSP6  NM_001946  Dual specificity phosphatase 6  -2.14 
EIF4E  NM_001968  Eukaryotic translation initiation factor 4E  -1.61 
MAPKAPK5 NM_139078  Mitogen-activated  protein  kinase-activated protein kinase 5  -1.89 
MKNK2  NM_017572  MAP kinase-interacting serine/threonine kinase 2  2.57 
PLA2G4A  NM_024420  Phospholipase A2, group IVA (cytosolic, calcium-dependent)  -1.7 
PPP1R14B AF318364  Protein  phosphatase 1, regulatory (inhibitor) subunit 14B  -1.68 
PPP1R3C  NM_005398  Protein phosphatase 1, regulatory (inhibitor) subunit 3C  -1.69 
PXN NM_002859  Paxillin  -1.76 
SHC1  NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
Fatty acid biosynthesis pathway (Path 2) 
ACAA2  NM_006111  Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 
3-oxoacyl-Coenzyme A thiolase) 
-1.66 
FASN NM_004104  Fatty  acid  synthase  1.72 
HADH2  NM_004493  Hydroxyacyl-Coenzyme A dehydrogenase, type II  -1.62 
Insulin receptor signaling pathwat 
ARHQ  NM_012249  Ras homolog gene family, member Q  1.92 
EIF4E  NM_001968  Eukaryotic translation initiation factor 4E  -1.61 
IRS1  NM_005544  Insulin receptor substrate 1  1.6 
IRS2  AF073310  Insulin receptor substrate 2  7.88 
PPP1R14B AF318364  Protein  phosphatase 1, regulatory (inhibitor) subunit 14B  -1.68 
PPP1R3C  NM_005398  Protein phosphatase 1, regulatory (inhibitor) subunit 3C  -1.69 
SHC1  NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
Integrin signaling pathway
ACTA2  NM_001613  Actin, alpha 2, smooth muscle, aorta  -4.46 
ACTB NM_001101  Actin,  beta  -1.67 
ACTG1 NM_001614  Actin,  gamma  1  -1.83 
ACTG2  NM_001615  Actin, gamma 2, smooth muscle, enteric  -4.86 
ARHQ  NM_012249  Ras homolog gene family, member Q  1.92 
ARPC2  NM_152862  Actin related protein 2/3 complex, subunit 2, 34kDa  -1.66 
ARPC3  NM_005719  Actin related protein 2/3 complex, subunit 3, 21kDa  -1.66 
BCAR3  NM_003567  Breast cancer anti-estrogen resistance 3  -2.26 
Table 2. Signaling pathways and genes
a that were significantly altered in uterine leiomyoma (UtLM) cells following genistein (50 μg/ml) treatment
for 24 h. Genes, CDKN2B, CCNB2, MADH3, MYBL1, INHBA (activin A), INHBB (activin B) and TGFB2 are also named as P15, Cyclin
B2, Smad3, A-myb, Activin A, Activin B and TGF-β2Genistein regulates TGFβ pathway genes    285
Signaling pathways  Genes  Accession No.  Description  Fold change 
CAV1  BC006432  Caveolin 1, caveolae protein, 22 kDa  -2.84 
COL1A1  NM_000088  Collagen, type I, alpha 1  -3.41 
ILK NM_004517  Integrin-linked  kinase  -1.57 
ITGA2  NM_002203  Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)  -1.64 
LAMA1 AK091949  Laminin,  alpha  1  3.72 
MYLK  NM_053025  Myosin, light polypeptide kinase  -3.24 
PARVA NM_018222  Parvin,  alpha  -1.88 
PPP1R12A AF086032  Protein  phosphatase 1, regulatory (inhibitor) subunit 12A  -2.38 
PPP1R12B NM_032105 Protein  phosphatase 1, regulatory (inhibitor) subunit 12B  -3.98 
PXN NM_002859  Paxillin  -1.76 
SHC1  NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
VASP NM_003370  Vasodilator-stimulated  phosphoprotein  -2.07 
P38 MAPK signaling pathway 
DDIT3 NM_004083  DNA-damage-inducible  transcript  3  2.42 
MAPKAPK5 NM_139078  Mitogen-activated  protein  kinase-activated protein kinase 5  -1.89 
MKNK2  NM_017572  MAP kinase-interacting serine/threonine kinase 2  2.57 
PLA2G4A  NM_024420  Phospholipase A2, group IVA (cytosolic, calcium-dependent)  -1.7 
TGFB2  AK021874  Transforming growth factor, beta 2  -3.03 
TNFRSF6  NM_000043  Tumor necrosis factor receptor superfamily, member 6  -1.62 
Purine metabolism pathway 
ADARB1  NM_015833  Adenosine deaminase, RNA-specific, B1 (RED1 homolog rat)  1.67 
ADCY7 NM_001114  Adenylate  cyclase  7  -2.23 
AK2 NM_172199  Adenylate  kinase  2  -2.65 
AK5 BC012467  Adenylate  kinase  5  -1.9 
ATIC NM_004044  5-aminoimidazole-4-carboxamide  ribonucleotide 
formyltransferase/IMP cyclohydrolase 
-1.59 
DGUOK NM_080916  Deoxyguanosine  kinase  -1.56 
ENPP1  NM_006208  Ectonucleotide pyrophosphatase/phosphodiesterase 1  2.13 
HPRT1  NM_000194  Hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) 
-1.69 
IFNAR1  NM_000629  Interferon (alpha, beta and omega) receptor 1  -2.07 
IMPDH2  NM_000884  IMP (inosine monophosphate) dehydrogenase 2  1.5 
ITPA  NM_033453  Inosine triphosphatase (nucleoside triphosphate pyrophosphatase)  -1.67 
NT5C  NM_014595  5', 3'-nucleotidase, cytosolic  -1.55 
PAICS X53793 Phosphoribosylaminoimidazole  carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide synthetase 
-1.61 
PAPSS2 AF074331  3'-phosphoadenosine 5'-phosphosulfate synthase 2  -1.72 
PNPT1 NM_033109  Polyribonucleotide  nucleotidyltransferase  1  -1.63 
POLI  NM_007195  Polymerase (DNA directed) iota  -1.86 
REV3L  NM_002912  REV3-like, catalytic subunit of DNA polymerase zeta (yeast)  -1.82 
RRM2  BC030154  Ribonucleotide reductase M2 polypeptide  -2.9 
TGF-β signaling pathway 
BMP2  NM_001200  Bone morphogenetic protein 2  2.81 
INHBA  AK001903  Inhibin, beta A (activin A, activin AB alpha polypeptide)  -2.06 
INHBB  NM_002193  Inhibin, beta B (activin AB beta polypeptide)  -1.64 
MADH3  U68019  SMAD, mothers against DPP homolog 3 (Drosophila)  -1.78 
SERPINE1  NM_000602  Serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
-2.1 
SMURF1  NM_020429  E3 ubiquitin ligase SMURF1  -1.68 
TGFB2  AK021874  Transforming growth factor, beta 2  -3.03 
VEGF signaling pathway 
ACTA2  NM_001613  Actin, alpha 2, smooth muscle, aorta  -4.46 
ACTB NM_001101  Actin,  beta  -1.67 
ACTG1 NM_001614  Actin,  gamma  1  -1.83 
ACTG2  NM_001615  Actin, gamma 2, smooth muscle, enteric  -4.86 
Table 2. Continued286    Exp. Mol. Med. Vol. 44(4), 281-292, 2012
Signaling pathways  Genes  Accession No.  Description  Fold change 
EIF2S2  NM_003908  Eukaryotic translation initiation factor 2, subunit 2 beta, 38 kDa  -1.69 
ELAVL1  BC003376  ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R) 
-1.6 
PXN NM_002859  Paxillin  -1.76 
SHC1  NM_003029  SHC (Src homology 2 domain containing) transforming protein 1  -1.77 
VEGF  AK098750  Vascular endothelial growth factor  -1.6 
VEGFC  NM_005429  Vascular endothelial growth factor C  -2.92 
YWHAE U28936  Tyrosine  3-monooxygenase/tryptophan  5-monooxygenase 
activation protein, epsilon polypeptide 
-1.62 
aIdentified by analysis using Ingenuity Pathway Analysis software. 
Table 2. Continued
understand the function of how cells and integrated 
biological mechanisms are involved in UtLM growth 
inhibition, and possibly provide novel targets for 
clinical intervention.
Results
Microarray analysis of significantly altered genes
The expression profile of over 41,000 genes was 
studied in genistein-treated UtLM cells (http://www. 
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=vjcjruqa
seesmps&acc=GSE19477). Vehicle treated UtLM 
cells served as the reference for the expression 
profile. Signature genes were generated by Rosetta 
Resolver based on the criteria that genes were ≥
1.5-fold and P ≤0.001 throughout all replicates. A 
total of 541 differentially expressed genes were 
observed. Of these, 150 genes were up-regulated and 
391 genes were down-regulated in genistein-treated 
compared to vehicle-treated UtLM cells. These 
genes were considered signature genes and were 
used for further analysis using IPA. 
IPA
To further analyze the biological significance of 
signature genes, genes were characterized into 
networks, functions and signaling pathways by 
using IPA software according to Ingenuity Pathways 
Knowledge Base (IPKB, http://www.ingenuity.com). 
These networks, functions and signaling pathways 
were ranked according to IPA calculated scores, 
which is based on the significance of involved 
genes. Based on IPKB, signature genes were 
classified into multiple functions and pathways by 
IPA. Among these, six functions and twelve pathways 
which were identified by IPA with significance values 
less than or equal to 0.05 (Tables 1 and 2). In the 
present study, we selected the following genes, 
INHBA (activin A), INHBB (activin B), MADH3 
(Smad3) and TGF-β2 involved in TGF-β signaling 
pathway, and genes, CDK6, CDKN2B (P15), 
MYBL1 (A-myb) and CCNB2 (cyclin B2) in cell cycle 
regulation for further evaluation. We found that most 
of all selected genes were down-regulated in the 
high concentration of genistein treated UtLM cells 
except the CDK inhibitor, P15, which was up-regulated. 
Validation of selected function and signaling 
pathway genes
Based on the analysis results from IPA software, the 
eight selected genes were further validated by 
real-time RT-PCR. As shown in Figure 1, we found 
that the results of real-time RT-PCR showed similar 
patterns to that of the microarray, however, the data 
calculated from the results of real-time RT-PCR was 
higher compared to microarray data. For example, 
the expression of P15 was increased in genistein 
treated UtLM cells about 2-fold by microarray and 
11-fold by real-time RT-PCR, while gene expression 
of cyclin B2, CDK6 and A-myb displayed down- 
regulation of 1.96, 2.96, 3.41-fold change, respectively, 
in microarray analysis and showed 5, 3, 3-fold 
decreased expression, respectively, by using 
real-time RT-PCR (Figure 1A). For TGF-β signaling 
pathway genes, we found that gene expression of 
activin A, activin B, Smad3 and TGF-β2 were 
down-regulated by a 2.06, 1.64, 1.78 and 3.03-fold 
change, respectively, in microarray analysis, and 
down-regulated by a 2, 4, 2 and 3-fold change, 
respectively, by real-time RT-PCR (Figure 1B). The 
differences in the results has been attributed to 
differences in RT-PCR vs. microarray methodologies.
Decreased protein expression of activin A and Smad3 
in genistein-treated UtLM cells 
Activin A, is an active TGF-β ligand dimer assembled 
by two INHBA isoforms (activin A) which initiates 
cellular responses by binding to its receptors, that Genistein regulates TGFβ pathway genes    287
Figure  1. Relative mRNA expression changes of selected pathway 
genes in uterine leiomyoma (UtLM) cells following genistein (50 μg/ml) 
treatment for 24 h, as measured by microarray (Gen-Microarray) and re-
al-time RT-PCR (Gen-RT-PCR). Results are calculated as the mRNA fold 
change by dividing values by the vehicle control (set at 1). Data are pre-
sented as mean ± S.E. of three experiments. A statistically significant 
difference (P ≤ 0.05) is indicated by asterisk(s) (*: genistein treated ver-
sus vehicle control with the method of microarray; **: genistein treated 
versus vehicle control with the method of real-time RT-PCR). A house 
keeping gene, GAPDH, was used for normalization. (A) Genes related to 
cell cycle regulation. (B) Genes in TGF-β signaling pathway. 
Figure 2. (A) Protein expression of activin A and Smad3 in uterine leio-
myoma (UtLM) cells following genistein (50 μg/ml) treatment for 24 h. 
Hypoxanthine phosphoribosyl-transferase (HPRT) was used as a protein 
loading control for each experiment. (B) Bar graphs show the mean ±
S.E. values of densitometry data of three experiments by dividing values 
by the vehicle control (set at 1). A statistically significant difference (P ≤
0.05) is indicated by an asterisks (*: genistein treated versus vehicle con-
trol).
Figure 3. (A) Protein expression of 
activin A and Smad3 in uterine leio-
myomas (L) and patient-matched 
myometrium (M). Hypoxanthine 
phosphoribosyl-transferase (HPRT) 
was used as a protein loading con-
trol for each experiment. (B) Bar 
graphs show the mean ± S.E. val-
ues of densitometry data of three 
experiments by dividing values by 
patient-matched myometrium (set at 
1). (C) Bar graphs shows the com-
parison of activin A and Smad3 pro-
tein expression between leiomyoma 
and patient-matched myometrial 
tissue.
have intrinsic serine/threonine kinase activity, and 
activating downstream Smad proteins (Abe et al., 
2004). Because gene and mRNA expression of 
activin A, activin B and Smad3 was down-regulated 
in genistein-treated UtLM cells, we did further 
studies to determine if the protein expression of 
activin A and Smad3 correlated with gene down- 
regulation in genistein-treated UtLM cells. Using 
western blotting, we found that the protein expression 
of both activin A and Smad3 was decreased in 
genistein-treated UtLM cells compared to vehicle- 
treated (Figure 2), suggesting that the decreased 
protein expression of activin A and Smad3 might 
due to the down-regulation of INHBA and Smad3 
genes, possibly leading to the inhibitory effects of 
genistein on UtLM cells. 
Comparison of activin A and Smad3 protein 
expression between uterine leiomyomas and 
matched myometrium in tissue samples
We examined the protein expression of activin A and 
Smad3 in sixteen leiomyomas and patient-matched 
myometrial tissue samples by western blotting to 
determine whether both of the protein levels of 
activin A and Smad3 are overexpressed in uterine 
leiomyomas compared to the matched myometrial 
tissue. We found that both protein expression of 
activin A and Smad3 were detectable in uterine 
leiomyomas and myometrium (Figure 3A). Although 288    Exp. Mol. Med. Vol. 44(4), 281-292, 2012
Figure  4. (A) Cell proliferation assay in treated UtLM cells, vehicle 
(control), 50 mg/ml of genistein (Gen-50), 20 nM activin A or genistein 
plus 20 nM activin A (Gen-50 + Acitivin A) for 96 h. The bar graph shows 
the mean ± S.E. values of absorbance of three experiments that have 
been normalized to the vehicle control (set at 1). a, b, c and d indicate 
groups which are statistically different (P ≤ 0.05). (B) Cell cycle analysis 
in treated UtLM cells, vehicle (control), 50 mg/ml of genistein (Gen-50), 
20 nM activin A or genistein plus 20 nM activin A (Gen-50 + Acitivin A) for 
48 h. The values represent the number of cells in the different phases of 
the cell cycle as a percentage of total cells observed. 
no statistical significance was found, in the comparison 
of uterine leiomyomas and matched myometrial 
tissue (Figure 3B), activin A protein levels were 
higher in leiomyoma than myometrial tissue in 56% 
(9/16) of the samples; equal in 31% (5/16) of the 
samples; and lower in 13% (2/16) of the samples 
(Figure 3C). The protein expression level of Smad3 
was higher in 62% (10/16) of the leiomyoma as 
compared to their matched myometrial tissue; equal 
in 25% (4/16) of the samples; and lower in 
leiomyoma than myometrial tissue in 13% (2/16) of 
the samples. Moreover, a positive correlation was 
found between the protein expression of activin A 
and Smad3 in both leiomyomas and matched 
myometrial tissue (Figures 3A and 3B), suggesting 
that signaling of TGF-β pathway, from activin A to 
Smad3 may have a promotional effect on the growth 
of leiomyomas.
Activin A stimulates growth of UtLM cells 
In order to gain information on the biological effects 
of activin A on UtLM cells growth, we utilized a 
recombinant activin A protein and examined its 
effects by cell proliferation assays. We found that 
when UtLM cells were treated with activin A (20 nM) 
for 5 days, the growth of UtLM cells was stimulated 
and the number of UtLM cells was significantly 
higher than vehicle-treated (P ＜0.05) (Figure 4). 
Furthermore, when UtLM cells were treated with a 
high concentration of genistein in combination with 
activin A, we found that the inhibitory effect of genistein 
was partially antagonized (P ＜0.05) (Figure 4). 
Therefore, the results further support the hypothesis 
that downregulation of activin A expression by 
genistein may inhibit the growth of UtLM cells.
Activin A increases percentage of UtLM cells in S 
phase
We conducted cell cycle analysis studies using flow 
cytometry to support our findings of activin A induced 
increased proliferation in UtLM cells. We found that 
activin A increased the percentage of cells in S 
phase in UtLM cells at 48 h (Figure 4). Additionally, 
when UtLM cells were treated with a high concen-
tration of genistein in combination with activin A, we 
found the percentage of cells in G2-M increased. 
These results support the positive growth effects ob-
served in UtLM cells following activin A treatment 
and the ability of activin A to rescue UtLM cells from 
the inhibitory growth effects observed with a high 
concentration of genistien. These data supports the 
proliferation data and further strengthens the hy-
pothesis that genestein’s down regulation of activin 
A may contribute to its negative growth effect in 
UtLM cells.
Discussion
The purpose of the present study was to identify the 
novel pathways and genes that might be involved in 
the inhibitory effect of a high dose of genistein on 
UtLM cells. Using DNA microarray and IPA, we 
identified genes, functions and pathways that may 
contribute to the inhibitory effect of genistein on 
UtLM cells. Most importantly, the possible role of 
TGF-β pathway genes, activin A and Smad3 in the 
pathogenesis of human uterine leiomyomas was 
ascertained. 
    The growth-inhibitory or apoptosis-inducing effects 
of genistein at high concentrations are mostly 
reported in in vitro studies (Jamadar-Shroff et al., 
2009; Pavese et al., 2010). By using DNA 
microarray, specific gene expression patterns have 
been reported in several different cell types under 
genistein treatment (Piao et al., 2006; Lee et al., 
2007; Lavigne et al., 2008). Consistently, in the 
present study we found that genes, related to cell 
cycle progression, such as BID, CASP3, MAP3K14, 
TNFRSF6, A-myb, CDK6, cyclin B2, Smad3 and 
E2F4 were significantly downregulated in genistein- 
treated UtLM cells. We also found that p15, a p53 
inducible gene, was induced in UtLM cells. This is 
consistent with the reported genotoxic/DNA damaging 
effect of high doses of genistein (Ye et al., 2004) and 
also is consistent with our previous report of 
decreased apoptosis in UtLM cells treated with a 
high dose of genistein compared to uterine myometrial Genistein regulates TGFβ pathway genes    289
(UtSMC) cells (Moore et al., 2007). Herein, our 
results suggest that regulations of cycle-related genes 
may be a molecular signature and mechanism of 
action for high doses of genistein on UtLM cell growth. 
    In addition to these genes discussed above, we 
also found that genistein at a high dose down-regulates 
TGF-β signaling pathway genes in UtLM cells. Smad3 
is one of two homologous proteins that involved in 
signaling from TGF-beta/activin to modulate gene 
transcription (ten Dijke and Hill, 2004). In leiomyoma, 
the protein expression of Smad3 as well as several 
other components of the TGF-β system, such as 
TGF-β receptors and Smad4, was found elevated 
compared to matched myometrium, and was 
lowered after GnRHa therapy (Chegini et al., 2003; 
Levens et al., 2005). Increased expression of Smad3 
and TGF-β receptors may account for the development 
of leiomyoma and its matrix components. Therefore, 
downregulation of Smad3 mRNA expression and 
decreased protein expression in UtLM cells may 
contribute to the inhibitory effects of high doses of 
genistein. Consistent with previous studies, in the 
present study, we have confirmed that the protein 
expression of Smad3 is increased in the leiomyomas 
more than matched myometrial tissue (Chegini et 
al., 2003). Additionally, we also demonstrated that 
activin A which is assembled by two INHBA isoforms, 
was lowered in genistein-treated UtLM cells. Activin 
A, as a member of TGF-β family, controls many 
physiological processes such as cell proliferation 
and differentiation, immune responses, wound 
repair and various endocrine activities (Harrison et 
al., 2005). Herein, we speculate that the inhibition 
effects of genistein in UtLM cells might be due to the 
down-regulation of activin A and Smad3, or possibly 
due to the inhibition of the TGF-β signaling, which 
transducts from activin A to Smad3. Elevation of 
TGF-βs has been reported in uterine leiomyomas 
(Levens et al., 2005; Luo et al., 2005; Zhao et al., 
2007); however, the protein expression of activin A 
has never been investigated. It was reported that in 
the ovaries of vertebrates, activins are expressed 
predominantly in the follicular layer of the oocyte where 
they regulate processes such as folliculogenesis, 
steroid hormone production, and oocyte maturation 
(Hogg, et al., 2010; McLaughlin, et al., 2010). In our 
present study, the presence of an increased protein 
expression of activin A in leiomyomas provided 
further information that activin A may play a role to 
elevate the growth of uterine leiomyoma. Herein, the 
results from tissue samples are further supportive of 
the importance of the TGF-β system as key 
regulator of leiomyoma growth. Activin A has 
various effects on diverse biological systems (Abe et 
al., 2004). In contrast to the report that activin A 
mediates growth inhibition and cell cycle arrest 
through Smads in human breast cancer cells 
(Burdette  et al., 2005), the stimulatory effect on 
mesenchymal cells such as fibroblasts has 
emphasized the importance of activin A in keloid 
pathogenesis (Mukhopadhyay et al., 2007). In the 
present study, we found that the growth of UtLM 
cells was increased by activin A and the inhibitory 
effect of a high-dose of genistein was antagonized 
by co-treatment with activin A. The stimulatory effect 
of activin A on UtLM cell growth is similar to TGF-β, 
which has been emphasized as one of the 
promoters in the formation of the extracellular matrix 
(Leppert et al., 2006). Also, we found that activin A 
was able to stimulate UtLM cells to progress into the 
S phase, in addition to promoting the progression of 
cells into mitosis when administered with a high 
concentration of genistein. These results further 
suggest that signaling of TGF-β pathway; from 
activin A to Smad3 may have a promotional effect on 
the growth of leiomyomas.
    In summary, by using IPA, along with multiple 
altered functions and signaling pathways, we were 
able to identify that cell cycle dysregulation and 
down-regulation of the TGF-β signaling pathway 
might contribute to the inhibitory effects of a high 
dose of genistein in UtLM cells. Using additional 
complimentary experiments, we were able to show 
that activin A and Smad3, both members of the 
TGF-β signaling pathway, may offer a mechanistic 
explanation for the progression of leiomyomas, and 
that these pathways and genes might be potential 
therapeutic targets for uterine fibroids.
Methods
Cell culture 
Human uterine leiomyoma (UtLM) cells (GM10964) were 
purchased from Coriell Institute for Medical Research 
(Camden, NJ), and cultured as previously reported (Swartz 
et al., 2005). Briefly, cells were grown in Eagle’s minimum 
essential medium (Invitrogen [Gibco], Carlsbad, CA) with 
19% fetal bovine serum (FBS) (Sigma, St Louis, MO) and 
supplemented with vitamins, essential and non-essential 
amino acids and L-glutamine (Invitrogen). All culture main-
tenance and experiments were performed at 37°C and 5% 
CO2. UtLM cells were seeded in T175 flasks (at passages 
8-14 at 80-95% confluence), and 24 h prior to treatment, 
the media was changed to Dulbecco’s modified Eagle’s 
medium/nutrient mixture F-12 Ham (DMEM/F-12) (Hyclone 
Laboratories, Logan, UT) phenol red-free with charcoal 
dextran treated FBS (Sigma). Cells were then treated with 
either genistein (50 μg/ml) (4’, 5, 7-Trihydroxyisoflavone; 
Sigma Chemical Company, St. Louis, MO) or the vehicle 
control [0.3% dimethylsulfoxide (DMSO), Sigma] in phenol 
red-free, stripped-serum DMEM medium for 24 h.290    Exp. Mol. Med. Vol. 44(4), 281-292, 2012
RNA isolation and microarray analysis 
Total RNA preparation for microarray studies was per-
formed as previously described (Swartz et al., 2005). Briefly, 
total RNA was isolated with TRIzol agent (Invitrogen) from 
treated UtLM cells and purified using a RNeasy MidiKit 
(QIAGEN, Valencia, CA), according to the manufacturers’ 
protocols. Due to the expense of chip printing and the large 
amount of RNA needed for each of the hybridizations, the 
samples from the flasks that received the same treatment 
were pooled, then concentrated to ＞9 μg/μl by Microcon 
30 columns (Amicon: Millipore, Bedford, MA). Gene ex-
pression analysis was conducted using Agilent Whole 
Human Genome arrays (Agilent Technologies, Palo Alto, 
CA). Total RNA was amplified by using the Agilent Low 
RNA Input Fluorescent Linear Amplification Kit protocol. 
Starting with 500 ng of total RNA, cyanine (Cy) 3- or 
Cy5-labeled cRNAs were produced according to manu-
facturer's protocol. For each two-color comparison, 750 ng 
each of Cy3- and Cy5-labeled cRNAs were mixed and frag-
mented using the Agilent In Situ Hybridization Kit protocol. 
Hybridizations were performed for 17 h in a rotating oven 
using the Agilent 60-mer Oligo microarray processing 
protocol. Slides were later washed as indicated in this pro-
tocol, and then scanned with an Agilent Scanner. Data 
were obtained using the Agilent Feature Extraction soft-
ware (v7.5), employing defaults for all parameters. Since 
only those genes that were consistently under- or over-ex-
pressed on three of four chip replicates were used, results 
from these pooled samples represent mean changes be-
tween the replicates. 
Rosetta resolver 
This procedure was performed as previously described 
(Kim et al., 2006). Images and GEML (gene expression 
markup language) files, including error and P-values, were 
exported from the Agilent Feature Extraction software and 
deposited into Rosetta Resolver (version 4.0, build 
4.0.1.0.7.RSPLIT) (Rosetta Biosoftware, Kirkland, WA). 
Ratio profiles were combined and intensity plots were gen-
erated for each ratio experiment. “Signature genes” were 
identified, as those having a P-value  ≤0.001 with a 
fold-change ≥1.5 in all three biological replicates. 
Ingenuity pathways analysis (IPA) 
Signature genes were further analyzed with IPA software 
(Ingenuity Systems, Redwood City, CA; http://www.ingenuity. 
com), a web-delivered application that makes use of the 
Ingenuity Pathways Knowledge Base (IPKB) containing 
large amounts of individually modeled relationships be-
tween gene objects (e.g., genes, mRNAs, and proteins). 
The procedure was performed as previously described (Liu 
et al., 2006). Briefly, we uploaded a tab-delimited text file 
with gene identifiers and their corresponding expression 
values such as fold-change and p-value. Each gene identi-
fier was mapped to its corresponding gene object in the 
Ingenuity Pathways Knowledge Base. A fold change cutoff 
of 1.5-fold and P ＜0.001 was set to identify genes whose 
expression was differentially regulated. These genes, 
called “focus genes,” were then used as the starting point 
for generating biological networks. To start building net-
works, the application queries the Ingenuity Pathways 
Knowledge Base for interactions between focus genes and 
all other gene objects stored in the knowledge base, then 
generates a set of networks with a network size of approx-
imately 35 genes or proteins. Ingenuity Pathways Analysis 
then computes a score for each network according to the 
fit of the user’s set of significant genes. The score is de-
rived from a P-value and indicates the likelihood of the fo-
cus genes in a network being found together because of 
random chance. A score of 2 indicates a 1 in 100 change 
that the focus genes are together in a network because of 
random chance. Therefore, scores of 2 or higher have at 
least a 99% confidence level of not being generated by 
random chance alone. Biological functions are then calcu-
lated and assigned to each network. 
Real-time RT-PCR analysis 
Real-time RT-PCR analysis was used to quantify the levels 
of expression of the selected genes (Supplemental Data 
Table S1). The forward and reverse primers for selected 
genes were designed using ABI Primer Express software 
(Applied Biosystems, Foster City, CA). Total RNA was pre-
pared as above and reverse transcribed with MuLV reverse 
transcriptase and oligo-dT primers (Applied Biosystems), 
then subjected to an ABI Prism 7900 Sequence Detection 
System using SYBR green PCR master mix (Applied 
Biosystems, Cheshire, UK), according to the manu-
facturer’s recommendations (Applied Biosystems). The 
threshold cycle (CT) values of the real-time PCR were 
used in the determination of the relative differences in ex-
pression between groups. To quantify the gene transcripts, 
we monitored GAPDH, which served as the internal quanti-
tative control. Each sample was normalized by quantifica-
tion against its GAPDH content. To determine the normal-
ized value, 2
-(ΔΔCT) values were compared between control 
and genistein treated groups, where the changes in cross-
ing threshold (ΔCT)=CtTarget gene-Ct GAPDH RNA, and ΔΔCT=
ΔCt
control- ΔCt
target as outlined in the Applied Biosystems 
protocol, and the results are presented as fold change 
above control.
Western blotting analysis 
Total protein was extracted from treated cells and tissue 
samples as previously described in our lab (Dixon et al., 
2002; Swartz et al., 2005). Then protein was separated on 
a 4-12% Nu-Page Bis-Tris (Invitrogen) gel, transferred to a 
0.45 μM PVDF membrane and probed with a monoclonal 
anti- human/mouse/rat activin A (1 : 500; MAB3381, R&D 
Systems Inc., Minneapolis, MN) and a Smad3 (1 : 1000 di-
lution; Sc-8332, Santa Cruz Biotechnology, Santa Cruz, 
CA). Recombinant human/mouse/rat activin A (338-AC, 
R&D Systems Inc.), was used as positive control. Signals 
were developed by using ECL Western Blotting Analysis 
System (Amersham pharmacia, Piscataway, NJ) according 
to the manufacturer’s protocol. A densitometer (Fluor 
ChemTM8900, Alpha Innotech, San Leandro, CA) was 
used for quantitation of the band intensities.Genistein regulates TGFβ pathway genes    291
Cell proliferation assay
UtLM cells were seeded into 96-well plates at an initial 
density of 4 ×10
3 per well in 100 μl Eagle’s MEM 
(Invitrogen) supplemented with vitamins, amino acids and 
19% FBS, and then incubated with DMEM/F-12, phenol 
red-free with charcoal dextran treated FBS for 24 h. The 
UtLM cells were then cultured with vehicle control (0.3% 
DMSO), genistein (50 μg/ml) alone or genistein in combi-
nation with activin A (20 nM) or activin A alone for 96 h. 
Cell proliferation was measured by spectrophotometry us-
ing CellTiter 96
R AQu
eous One Solution Cell Proliferation as-
say (Promega Corporation, Madison, WI) according to the 
manufacturer’s protocol. All conditions were tested in five 
replicates in triplicate experiments.
Cell cycle analysis 
Flow cytometry was used to determine the percentage of 
cells in various phases of the cell cycle. The DNA content 
was determined using propidium iodide (PI) and ethanol 
fixation. Briefly, UtLM cells were treated with 0 μg/ml 
(DMSO; control), 50 μg/ml genistein (Sigma), 20 nM activin 
A (R & D Systems), or a combination of 50 μg/ml genistein 
and 20 nM activin A, and incubated in culture for 48 h. The 
UtLM cells were pelleted and fixed by the slow addition of 
cold 70% ethanol to a volume of approximately 2-3 ml with 
agitation. The volume was adjusted to 5 ml with cold 70% 
ethanol and the cells were stored at -20
oC overnight. Fixed 
cells were pelleted from the ethanol, washed once in 3 ml 
of 1X PBS and stained in 1 ml of 20 ng/ml propidium io-
dide, 1,000 units RNaseOne (Promega) in 1X PBS. 
Analysis was done using a Becton Dickinson FACSort flow 
cytometer and CELLQuest software (Becton Dickinson 
Immunocytometry Systems, San Jose, CA). Individual cells 
(7,500 per experimental sample) were selected by gating 
on a PI area versus width dot plot to exclude cell ag-
gregates and debris. Cells were excited using a 488 nm ar-
gon laser and emission was detected at 585 nm. Data was 
analyzed using Modfit software for Mac version 2.0.
Statistical analysis
The results are expressed as means ± S.E. (standard er-
ror). The gene expression data of quantitative RT-PCR ex-
periments were analyzed for statistical significance by a 
Student’s  t-test for two-tailed unpaired comparisons. 
Two-sided Mann-Whitney test was performed to determine 
the statistical significance of the results of protein ex-
pression and cell proliferation assay between different 
groups. A probability level of P-value ≤0.05 was consid-
ered significant.
Supplemental data
Supplemental data include a table and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-44-4-04.pdf.
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